Dr. Prato explores a critical reason why immunotherapy for cancer often falls short: T-cells and other immune cells can't reach the cancer cells.

He details a phenomenon where crucial t lymphocytes are blocked from entering tumors, preventing them from doing their job. Understanding this challenge in immunology is key to advancing effective cancer treatment strategies.

🎯 What You’ll Learn in This Episode

• What T-cell exclusion means
• Why immune cells may be blocked from tumors
• What “cold tumors” really are
• How tumor microenvironment affects treatment response
• The role of CXCR4 and CXCL12 signaling
• Why immunotherapy doesn’t work for every patient
• How immune positioning impacts outcomes
• Why personalized approaches are being explored

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Sometimes the immune system isn’t weak — it’s locked out.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493